Detalhe da pesquisa
1.
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Breast Cancer Res
; 20(1): 79, 2018 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30053900
2.
The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Acta Oncol
; 57(1): 44-50, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29202609
3.
Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Clin Breast Cancer
; 20(4): e423-e432, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32253134
4.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
NPJ Breast Cancer
; 6: 7, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32140564
5.
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
J Clin Oncol
; 36(8): 735-740, 2018 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29369732
6.
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Clin Cancer Res
; 22(3): 560-6, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26152740
7.
Sensitive assay for identification of methicillin-resistant Staphylococcus aureus, based on direct detection of genomic DNA by use of gold nanoparticle probes.
Clin Chem
; 50(10): 1949-52, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15319321